Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
51 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Equine Encephalitis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides an overview of the Equine Encephalitis (Central Nervous System) pipeline landscape. Equine encephalitis (EE) is mosquito transmitted disease that can cause severe inflammation of the brain (encephalitis) in humans. Symptoms include the sudden onset of fever, chills, body and joint aches. Infection can develop into severe encephalitis, resulting in headache, disorientation, tremors, seizures and paralysis. Permanent brain damage, coma and death may also occur in some cases. Approximately a third of patients who develop EE die, and many of those who survive have mild to severe brain damage. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Equine Encephalitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Equine Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Equine Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 8 and 3 respectively for Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 1 molecules, respectively for Equine Encephalitis. Equine Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Equine Encephalitis (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Equine Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Equine Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Equine Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Equine Encephalitis (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Equine Encephalitis (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Equine Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Equine Encephalitis Overview 7 Therapeutics Development 8 Pipeline Products for Equine Encephalitis - Overview 8 Pipeline Products for Equine Encephalitis - Comparative Analysis 9 Equine Encephalitis - Therapeutics under Development by Companies 10 Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes 11 Equine Encephalitis - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Equine Encephalitis - Products under Development by Companies 14 Equine Encephalitis - Products under Investigation by Universities/Institutes 15 Equine Encephalitis - Companies Involved in Therapeutics Development 16 Akshaya Bio Inc. 16 Altravax, Inc. 17 EpiVax, Inc. 18 Integrated BioTherapeutics, Inc. 19 Karyopharm Therapeutics, Inc. 20 Profectus BioSciences, Inc. 21 Equine Encephalitis - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 DEF-201 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 equine encephalitis vaccine - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 equine encephalitis vaccine - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 equine encephalitis vaccine - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 imatinib mesylate - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 nilotinib - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 TSI-GSD-104 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Vaccine for Western Equine Encephalitis - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 venezuelan equine encephalitis vaccine - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Venezuelan equine encephalitis vaccine - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 venezuelan equine encephalitis vaccine - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 verdinexor - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Westrern Equine Encephalitis Virus Vaccine - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Equine Encephalitis - Dormant Projects 47 Equine Encephalitis - Product Development Milestones 48 Featured News & Press Releases 48 Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses 48 Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses 48 Appendix 50 Methodology 50 Coverage 50 Secondary Research 50 Primary Research 50 Expert Panel Validation 50 Contact Us 50 Disclaimer 51
List of Tables
Number of Products under Development for Equine Encephalitis, H2 2016 8 Number of Products under Development for Equine Encephalitis - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Equine Encephalitis - Pipeline by Akshaya Bio Inc., H2 2016 16 Equine Encephalitis - Pipeline by Altravax, Inc., H2 2016 17 Equine Encephalitis - Pipeline by EpiVax, Inc., H2 2016 18 Equine Encephalitis - Pipeline by Integrated BioTherapeutics, Inc., H2 2016 19 Equine Encephalitis - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 20 Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H2 2016 21 Assessment by Monotherapy Products, H2 2016 22 Number of Products by Stage and Target, H2 2016 24 Number of Products by Stage and Mechanism of Action, H2 2016 26 Number of Products by Stage and Route of Administration, H2 2016 28 Number of Products by Stage and Molecule Type, H2 2016 30 Equine Encephalitis - Dormant Projects, H2 2016 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.